Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update

Current Diabetes Reports

Volumn 7, Issue 3, 2007, Pages 208-217

  Ganne, Sudha ^b   Arora, Surender K ^b   Dotsenko, Olena ^b   McFarlane, Samy I ^b   Whaley Connell, Adam ^a  

^a University of Missouri   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; RAMIPRIL; RENIN; RENIN INHIBITOR; ROSIGLITAZONE; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; UNINDEXED DRUG;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COUGHING; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; EPIDEMIC; EXERCISE; GENETIC PREDISPOSITION; GEOGRAPHIC DISTRIBUTION; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STROKE; VASCULAR ENDOTHELIUM; VASODILATATION; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; LIFE STYLE; METABOLIC SYNDROME X; RENIN-ANGIOTENSIN SYSTEM;

EID: 34250744676     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0033-3     Document Type: Review

References (72)

1. Lorenzo C, Okoloise M, Williams K, et al.: The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 2003, 26:3153-3159.
2. Palaniappan L, Carnethon MR, Wang Y, et al.: Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004, 27:788-793.
3. Eckel RH, Grundy SM, Zimmer PA: The metabolic syndrome. Lancet 2005, 365:1415-1428.
4. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
5. Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA 2002, 288:2709-2716.
6. Girman CJ, Rhodes T, Mercuri M, et al.: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93:136-141.
7. Malik S, Wong ND, Franklin SS, et al.: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245-1250.
8. Chobanian AV, Bakris GL, Black HR, et al.: Seventh report of the joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, JAMA 2003, 289:2560-2571.
9. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001, 86:713-718.
10. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374-381.
11. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053-1059.
12. Grunfeld B, Balzareti M, Romo M, et al.: Hyperinsulinemia in normotensive offspring of hypertensive parents. Hypertension 1994, 23(suppl 1):112-115.
13. Steinberg HO, Chaker H, Learning R, et al.: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97:2601-2610.
14. El-Atat F, Aneja A, McFarlane S, Sowers J: Obesity and hypertension. Endocrinol Metab Clin North Am 2003, 32:823-854.
15. Sowers JR: Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004, 286:H1597-H1602.
16. Castro JP, El-Atat FA, McFarlane SI, et al.: Cardiometabolic syndrome: pathopbysiology and treatment. Curr Hypertens Rep 2003, 5:393-401.
17. Tuck ML, Sowers J, Dornfield L, et al.: The effect of weight reduction on blood pressure plasma renin activity and plasma aldosterone level in obese patients. N Engl J Med 1981, 304:930-933.
18. Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127-137.
19. Weyer C, Pratley RE, Snitker Spraul M, et al.: Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000, 36:531-537.
20. Landsberg L, Young JB: Insulin-mediated glucose metabolism in the relationship between dietary intake and sympathetic nervous system activity. Int J Obes 1985, 9(suppl 2):63-68.
21. Zhang R, Reisin E: Obesity-hypertension: the effects on cardiovascular and renal systems. Am J Hypertens 2000, 13:1308-1314.
22. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999, 353:611-616.
23. Yusuf S, Sleight P, Pogue Bosch J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
24. Lindholm LH, Ibsen H, Borch-Johnsen K, et al.: Risk of new-onset diabetes in the Losartan Intervention For End-point reduction in hypertension study. J Hypertens 2002, 20:1879-1886.
25. Henriksen EJ, Jacob S, Kinnick TR, et al.: Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001, 38:884-890.
26. El-Atat F, McFarlane SI, Sowers JR: Diabetes, hypertension and cardiovascular derangements: update on the pathophysiology and management. Curr Hypertens Rep 2004, 6:215-223.
27. McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91:30H-37H.
28. Schupp M, Janke J, Clasen R, et al.: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057.
29. Weiss R, Dufour S, Taksali SE, et al.: Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 2003, 362:951-957.
30. Sharma AM, Janke J, Gorzelniak K, et al.: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609-611.
31. Garrison RJ, Kannel WB, Stokes J, Castelli WP: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16:234-251.
32. McFarlane SI, Winer N, Sowers JR: Role of the natriuretic peptide system in cardiorenal protection. Arch Intern Med 2003, 163:2696-2704.
33. Sarzani R, Dessi-Fulgheri P, Salvi F, et al.: A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 1999, 17:1301-1305.
34. McFarlane SI, Sowers JR: Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab 2003, 88:516-523.
35. Nannipieri M, Seghieri G, Catalano C, et al.: Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. Horm Metab Res 2002, 34:265-270.
36. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210-1214.
37. Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
38. Dekker JM, Girman C, Rhodes T, et al.: Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005, 112:666-673.
39. Olshansky SJ, Passaro DJ, Hershow RC, et al.: A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005, 352:1138-1145.
40. Whaley-Connell A, Palmer J, Sowers JR: Risk stratification and treatment options for hypertensive patients with metabolic syndrome and prediabetes. Johns Hopkins Advanced Studies in Medicine 2005, 5:S1011-S1018.
41. Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344:3-10.
42. Obarzanek E, Sacks FM, Vollmer WM, et al.: Effects on blood lipids of a blood pressure lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr 2001, 74:80-89.
43. American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2002, 25(suppl 1):S71-S73.
44. Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000, 36:646-661.
45. Stamler J, Vaccaro O, Neaton JD, Wentworth D.: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
46. Hebert PR, Moser M, Mayer J, et al.: Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993, 153:578-581.
47. Moser M. Hebert PR: Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996, 27:1214-1218.
48. Psaty BM, Smith NL, Siscovick DS, et al.: Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997, 277:739-745.
49. Staessen JA, Fagard R, Thijs L, et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757-764.
50. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [no authors listed]. JAMA 1991, 265:3255-3264.
51. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
52. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351:1755-1762.
53. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk ypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002, 288:2981-2997.
54. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group [no authors listed]. BMJ 1998, 317:713-720.
55. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 2002, 359:1004-1010.
56. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
57. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
58. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
59. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators [no authors listed]. Lancet 2000, 355:253-259.
60. Khan K, Govindarajan G, Whaley-Connell A, Sowers JR: Diabetic hypertension. Heart Failure Clinics 2006, 2:25-36.
61. Sowers JR, Reed J: 1999 Clinical advisory treatment of hypertension in diabetes. J Clin Hypertens (Greenwich) 2000, 2:132-133.
62. Larochelle P, Clack JM, Marbury TC, et al.: Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997, 80:1613-1615.
63. Whaley-Connell A, Sowers JR: Hypertension management in type 2 diabetes and the JNC VII. In Endocrinology and Metabolism Clinics of North Amercia. Edited by Einhorn D, Rosenstock J. Philadelphia: WB Saunders Company; 2005:63-75.
64. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
65. American Diabetes Association: Nephropathy in diabetes: clinical practice recommendations. Diabetes Care 2004, 27(suppl 1):S79-S83.
66. Pfeffer MA, Swedberg K, Granger CB, et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
67. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
68. Gerstein HC, Yusuf S, Holman R, et al.: Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004, 47:1519-1527.
69. Wing LM, Reid CM, Ryan P, et al.: A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583-592.
70. Pyorala K, Ballantyne CM, Gumbiner B, et al.: Reduction of cardiovascular events by sinivastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004, 27:1735-1740.
71. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998, 98:2513-2519.
72. Armitage J, Collins R: Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials MRC/BHF Heart Protection Study. Heart 2000, 84:357-360.